LUYE PHARMA (02186) Successfully Includes Five New Products in 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory

Stock News12-07

LUYE PHARMA (02186) announced that five of its new products have been successfully included in either the "National Reimbursement Drug List (2025)" or the "Commercial Health Insurance Innovative Drug Directory (2025)" issued by the National Healthcare Security Administration.

The five newly included products are: Mephiboxin® (Oxycodone Naloxone Extended-Release Tablets) and Rebalax® (Paliperidone Palmitate Injection (II)), which were newly added to the National Reimbursement Drug List; Zanbika® (Lurbinectedin for Injection) was selected for the Commercial Insurance Innovative Drug Directory; while Betovel® (Goserelin Acetate Microspheres for Injection) and Rekotuo® (Risperidone Microspheres for Injection (II)) were successfully renewed and remain on the National Reimbursement Drug List.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1151283630?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-07 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151283630","market":"hk","top_or_hot":-1,"title":"LUYE PHARMA (02186) Successfully Includes Five New Products in 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory","media":"Stock News","content":"<p>LUYE PHARMA (02186) announced that five of its new products have been successfully included in either the \"National Reimbursement Drug List (2025)\" or the \"Commercial Health Insurance Innovative Drug Directory (2025)\" issued by the National Healthcare Security Administration.</p>\n<p>The five newly included products are: Mephiboxin® (Oxycodone Naloxone Extended-Release Tablets) and Rebalax® (Paliperidone Palmitate Injection (II)), which were newly added to the National Reimbursement Drug List; Zanbika® (Lurbinectedin for Injection) was selected for the Commercial Insurance Innovative Drug Directory; while Betovel® (Goserelin Acetate Microspheres for Injection) and Rekotuo® (Risperidone Microspheres for Injection (II)) were successfully renewed and remain on the National Reimbursement Drug List.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LUYE PHARMA (02186) Successfully Includes Five New Products in 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLUYE PHARMA (02186) Successfully Includes Five New Products in 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-07 18:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LUYE PHARMA (02186) announced that five of its new products have been successfully included in either the \"National Reimbursement Drug List (2025)\" or the \"Commercial Health Insurance Innovative Drug Directory (2025)\" issued by the National Healthcare Security Administration.</p>\n<p>The five newly included products are: Mephiboxin® (Oxycodone Naloxone Extended-Release Tablets) and Rebalax® (Paliperidone Palmitate Injection (II)), which were newly added to the National Reimbursement Drug List; Zanbika® (Lurbinectedin for Injection) was selected for the Commercial Insurance Innovative Drug Directory; while Betovel® (Goserelin Acetate Microspheres for Injection) and Rekotuo® (Risperidone Microspheres for Injection (II)) were successfully renewed and remain on the National Reimbursement Drug List.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159992","symbol_name":"创新药","start_time":0,"source_url":"","article_id":"1151283630","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151283630","pubTimestamp":1765104372,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LUYE PHARMA (02186) announced that five of its new products have been successfully included in either the \"National Reimbursement Drug List (2025)\" or the \"Commercial Health Insurance Innovative Drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","BK1583":"高瓴概念","BK1191":"制药","BK1161":"生物科技","06978":"永泰生物-B","BK1606":"中医药概念","BK1574":"生物医药B类股","02186":"绿叶制药"},"translate_title":"绿叶制药(02186)五款新品成功纳入2025年国家报销药品目录或商保创新药目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"06978":1,"02186":1},"content_text":"LUYE PHARMA (02186) announced that five of its new products have been successfully included in either the \"National Reimbursement Drug List (2025)\" or the \"Commercial Health Insurance Innovative Drug Directory (2025)\" issued by the National Healthcare Security Administration.\nThe five newly included products are: Mephiboxin® (Oxycodone Naloxone Extended-Release Tablets) and Rebalax® (Paliperidone Palmitate Injection (II)), which were newly added to the National Reimbursement Drug List; Zanbika® (Lurbinectedin for Injection) was selected for the Commercial Insurance Innovative Drug Directory; while Betovel® (Goserelin Acetate Microspheres for Injection) and Rekotuo® (Risperidone Microspheres for Injection (II)) were successfully renewed and remain on the National Reimbursement Drug List.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151283630","isCrawlerRequest":true}